Eye Health News and Research

Latest Eye Health News and Research

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

Young women with indoor tanning habits frequently experience sunburn

Controversy remains over the risks involved with indoor tanning, especially in children and young adults. Since sunburn serves as a marker for excessive and skin-cell damaging ultraviolet (UV) exposure -- which can eventually lead to the development of skin cancer -- investigators at The Cancer Institute of New Jersey (CINJ) took a closer look at a college-aged sample of females and their indoor tanning habits.

31 Jul 2012

ATP1A3 gene mutations responsible for alternating hemiplegia of childhood

Alternating hemiplegia of childhood (AHC) is a rare disorder that usually begins in infancy, with intermittent episodes of paralysis and stiffness, first affecting one side of the body, then the other. Symptoms mysteriously appear and disappear, again and again, and affected children often experience dozens of episodes per week. As they get older, children fall progressively behind their peers in both intellectual abilities and motor skills, and more than half develop epilepsy.

31 Jul 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Scientists identify new gene responsible for genetic form of blindness in newborns

One of the mysteries of blindness has been solved. A team of international scientists in collaboration with the Research Institute of the McGill University Health Centre (RI MUHC) identified a new gene responsible for Leber Congenital Amaurosis (LCA), a devastating genetic form of blindness in newborns.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

New compound effective at blocking damage to the retina in diabetic retinopathy

Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

Researchers isolate elusive human gene that causes NMNAT1-related Leber congenital amaurosis

Researchers from the Massachusetts Eye and Ear Infirmary, The Children's Hospital of Philadelphia, Loyola University Chicago Health Sciences Division and their collaborators have isolated an elusive human gene that causes a common form of Leber congenital amaurosis (LCA), a relatively rare but devastating form of early-onset blindness. The new LCA gene is called NMNAT1.

30 Jul 2012

Brief treatments with accelerated resolution therapy reduce symptoms associated with PTSD

Researchers at the University of South Florida (USF) College of Nursing have shown that brief treatments with Accelerated Resolution Therapy (ART) substantially reduce symptoms associated with post-traumatic stress disorder (PTSD) including, depression, anxiety, sleep dysfunction and other physical and psychological symptoms.

28 Jul 2012

New device makes it possible to draw and write using just eye movements

A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).

28 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

AIDS 2012 plenary speakers call for innovative financing, continued research for HIV cure

Speakers at Tuesday's plenary session at the XIX International AIDS Conference in Washington, D.C. highlighted the challenges that lie ahead in the response to HIV/AIDS and discussed potential solutions, ABC News reports.

26 Jul 2012

Obama skipping AIDS conference; Black community still bearing high burden of the disease

For all the dignitaries on the schedule at the International AIDS Conference this week in Washington, including Secretary of State Hillary Clinton, Microsoft Corp. co-founder Bill Gates and former President Bill Clinton, it's the absence of one that has activists talking. With the conference being held in the U.S. for the first time in 22 years, President Barack Obama is out of town campaigning and raising money for his re-election. His only presence is a 50-second cameo in a three-minute video welcoming delegates.

26 Jul 2012

Assistant Sec. of Health Koh addresses AIDS 2012 plenary; HHS Sec. Sebelius speaks at Washington Post event

Speaking at the plenary session of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., on Monday, U.S. Assistant Secretary for Health Howard Koh discussed the development and implementation of the United States' first-ever comprehensive National HIV/AIDS Strategy, ABC News reports.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Eye Health News and Research

Latest Eye Health News and Research

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

Young women with indoor tanning habits frequently experience sunburn

ATP1A3 gene mutations responsible for alternating hemiplegia of childhood

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Scientists identify new gene responsible for genetic form of blindness in newborns

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

New compound effective at blocking damage to the retina in diabetic retinopathy

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Researchers isolate elusive human gene that causes NMNAT1-related Leber congenital amaurosis

Brief treatments with accelerated resolution therapy reduce symptoms associated with PTSD

New device makes it possible to draw and write using just eye movements

ACT receives Australian patent for human retinal pigment epithelial cells

Long-term use of reverse geometry lenses may induce inflammatory response

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Insomnia: an interview with Dr Darryle Schoepp

AIDS 2012 plenary speakers call for innovative financing, continued research for HIV cure

Obama skipping AIDS conference; Black community still bearing high burden of the disease

Assistant Sec. of Health Koh addresses AIDS 2012 plenary; HHS Sec. Sebelius speaks at Washington Post event

AAQ chemical temporarily restores vision in blind mice

AHAF announces glaucoma and macular degeneration research grants

Genetics & Genomics - Second Edition eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in